Ordinary shares, nominal value €0.10 per share
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 2.02, 9.01 · 8-K
DBV Technologies S.A.
DBVTFOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On October 28, 2026, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update →Company context
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.
Current securities
Registered securities in this filing
DBV Technologies S.A. · 8-K · Filed 2026-10-28
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
- Symbol
- DBVT
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition
On October 28, 2026, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 Press Release Châtillon, France, October 28, 2026 ─────────────────────────────────────── DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness towards the launch of the VIASKIN® Peanut Patch in children aged 4-7 years in the US, if approved Reported cash and cash equivalents of $165.7 million as of September 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, October 28, at 5:00pm ET ─────────────────────────────────────────────────────────────────── DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a late-stage specialty biopharmaceutical company, today reported financial results for the Third Quarter of 2026. The quarterly and nine months financial statements were approved by the Board of Directors on October 28, 2026. “The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now…
Open exhibit ↗